Efficacy and safety of aldose reductase inhibitor for the treatment of diabetic cardiovascular autonomic neuropathy: Systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Hu, Xin ^a   Li, Shengbing ^a   Yang, Gangyi ^a   Liu, Hua ^b   Boden, Guenther ^c   Li, Ling ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; PONALRESTAT; TOLRESTAT; ALDEHYDE REDUCTASE; ENZYME INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ANALYTICAL PARAMETERS; AUTONOMIC NEUROPATHY; BRAIN FUNCTION; CLINICAL EFFECTIVENESS; DATA ANALYSIS; DIABETIC CARDIOVASCULAR AUTONOMIC NEUROPATHY; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; EXPIRATION INSPIRATION RATIO; FUNCTIONAL ASSESSMENT; GLYCEMIC CONTROL; HEART FUNCTION TEST; HEART RATE; HUMAN; HYPERTRANSAMINASEMIA; LIVER NECROSIS; META ANALYSIS; OUTCOME ASSESSMENT; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHEMISTRY; DIABETES COMPLICATIONS; DIABETIC NEUROPATHIES; REPRODUCIBILITY; STATISTICAL MODEL; TREATMENT OUTCOME;

ALDEHYDE REDUCTASE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETIC NEUROPATHIES; ENZYME INHIBITORS; HEART RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84895732630     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087096     Document Type: Review

References (45)

1. Vinik AI, Maser RE, Mitchell BD, Freeman R (2003) Diabetic autonomic neuropathy. Diabetes Care 26:1553-1579. (Pubitemid 36934465)
2. Maser RE, Lenhard MJ (2005) Cardiovascular autonomic neuropathy due to diabetes mellitus: clinical manifestations, consequences, and treatment. J Clin Endocrinol Metab 90:5896-5903. (Pubitemid 41415509)
3. Schönauer M, Thomas A, Morbach S, Niebauer J, Schönauer U, et al. (2008) Cardiac autonomic diabetic neuropathy. Diabetes and Vascular Disease Research 5:336-344
4. Pop-Busui R (2010) Cardiac Autonomic Neuropathy in Diabetes. Diabetes Care: a clinical perspective. Diabetes Care 33:434-441.
5. Maser RE, Mitchell BD, Vinik AI, Freeman R (2003) The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care 6:1895-1901. (Pubitemid 36929140)
6. Edwards JL, Vincent AM, Cheng HT, Feldman EL (2008) Diabetic neuropathy: mechanisms to management. Pharmacol Ther 120:1-34.
7. Kelkar P (2005) Diabetic neuropathy. Semin Neurol 25:168-173.
8. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabó E, et al. (2002) The role of poly-(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes 51:514-521. (Pubitemid 34764811)
9. Oates PJ (2002) Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol 50:325-392.
10. El-Kabbani O, Ruiz F, Darmanin C, Chung RP (2004) Aldose reductase structures: implications for mechanism and inhibition. Cell Mol Life Sci 61:750-762. (Pubitemid 38650996)
11. Hamada Y, Nakamura J (2004) Clinical potential of aldose reductase inhibitors in diabetic neuropathy. Treat Endocrinol 3:245-255. (Pubitemid 38924091)
12. Chalk C, Benstead TJ, Moore F (2007) Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev 17:CD004572.
13. Goto Y, Hotta N, Shigeta Y, Sakamoto N, Kikkawa R (1995) Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother 49:269-77.
14. Giugliano D, Marfella R, Quatraro A, De Rosa N, Salvatore T, et al. (1993) Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial.
15. Giugliano D, Acampora R, Marfella R, Di Maro G, De Rosa N, et al. (1995) Tolrestat in the primary prevention of diabetic neuropathy. Diabetes Care 18:536-41.
16. Faes TJ, Yff GA, DeWeerdt O, Lanting P, Heimans JJ, et al. (1993) Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor. J Neurol 240:156-60. (Pubitemid 23091010)
17. Hotta N, Akanuma Y, Kawamori R, Matsuoka K, Oka Y, et al. (2006) Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 29:1538-1544. (Pubitemid 44127578)
18. Ikeda T, Iwata K, Tanaka Y (1999) Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 43:193-198. (Pubitemid 29202130)
19. Nakayama M, Nakamura J, Hamada Y, Chaya S, Mizubayashi R, et al. (2001) Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy. Diabetes Care 24:1093-1098. (Pubitemid 33716382)
20. Sundkvist G, Armstrong FM, Bradbury JE, Chaplin C, Ellis SH, et al. (1992) Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. J Diabetes Complications 6:123-130. (Pubitemid 23132712)
21. Ziegler D, Mayer P, Rathmann W, Gries FA (1991) One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy. Diabetes Res Clin Pract 14(1):63-73.
22. Gill JS, Williams G, Ghatei MA, Hetreed AH, Mather HM, et al. (1990) Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy. Diabete Metab 16(4):296-302.
23. O'Hare JP, Morgan MH, Alden P, Chissel S, O'Brien IA, et al. (1988) Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil. Diabet Med 5(6):537-542.
24. Johnson BF, Nesto RW, Pfeifer MA, Slater WR, Vinik AI, et al. (2004) Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration. Diabetes Care 27:448-454. (Pubitemid 38174070)
25. Krentz AJ, Honigsberger L, Ellis SH, Hardman M, Nattrass M (1992) A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy. Diabet Med 9:463-468.
26. Laudadio C, Sima AA (1998) Progression rates of diabetic neuropathy in placebo patients in an 18-month clinical trial. Ponalrestat Study Group. J Diabetes Complications 12:121-127. (Pubitemid 28241435)
27. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1-12. (Pubitemid 26120810)
28. Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available: http://www.cochrane-handbook.org.
29. Ewing DJ, Martyn CN, Young RJ, Clarke BF (1985) The value of cardiovascular autonomic function tests: 10 years' experience in diabetes. Diabetes Care 8:491-498. (Pubitemid 15240914)
30. Kahn R (1992) Proceedings of a consensus development conference on standardized measures in diabetic neuropathy. Autonomic nervous system testing. Diabetes Care 15:1095-1103.
31. Voulgari C, Tentolouris N, Stefanadis C (2011) The ECG vertigo in diabetes and cardiac autonomic neuropathy. Exp Diabetes Res Epub ahead of time.
32. Anonymous (1996) Assessment: clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 46:873-880.
33. Weimer LH (2010) Autonomic testing: common techniques and clinical applications. Neurologist 16:215-222.
34. Spallone V, Bellavere F, Scionti L, Maule S, Quadri R, et al. (2011) Diabetic Neuropathy Study Group of the Italian Society of Diabetology. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovasc Dis 21:69-78.
35. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, et al. (1999) Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896-1900.
36. Follmann D, Elliott P, Suh I, Cutler J (1992) Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45:769-773.
37. Cochran W (1954) The combination of estimated from different experiments. Biometrics 10:101-129.
38. Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Statist Med 21:1539-1558. (Pubitemid 34746062)
39. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188. (Pubitemid 17189972)
40. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748.
41. van Gerven JM, Lemkes HH, van Dijk JG (1992) Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy. J Diabetes Complications 6:45-8. (Pubitemid 23034750)
42. Karayannis G, Giamouzis G, Cokkinos DV, Skoularigis J, Triposkiadis F (2012) Diabetic cardiovascular autonomic neuropathy: clinical implications. Expert Rev Cardiovasc Ther 10:747-765.
43. Weimer LH (2010) Autonomic testing: common techniques and clinical applications. Neurologist 16:215-222.
44. Scott LA, Kench PL (2004) Cardiac autonomic neuropathy in the diabetic patient: does 123I-MIBG imaging have a role to play in early diagnosis? J Nucl Med Technol 32:66-71. (Pubitemid 47618978)
45. Vinik AI, Ziegler D (2007) Diabetic cardiovascular autonomic neuropathy. Circulation 115:387-397. (Pubitemid 46148513)